BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33913648)

  • 1. Polypill in Persons without Cardiovascular Disease.
    Gallieni M; Paik JM; Fiorina P
    N Engl J Med; 2021 Apr; 384(17):1673-1674. PubMed ID: 33913648
    [No Abstract]   [Full Text] [Related]  

  • 2. Polypill in Persons without Cardiovascular Disease.
    Cainzos-Achirica M
    N Engl J Med; 2021 Apr; 384(17):1675-1676. PubMed ID: 33913652
    [No Abstract]   [Full Text] [Related]  

  • 3. Polypill in Persons without Cardiovascular Disease.
    Wald N; Wald D; Law M
    N Engl J Med; 2021 Apr; 384(17):1675. PubMed ID: 33913651
    [No Abstract]   [Full Text] [Related]  

  • 4. Polypill in Persons without Cardiovascular Disease.
    Messerli FH; Brguljan J; Bangalore S
    N Engl J Med; 2021 Apr; 384(17):1674-1675. PubMed ID: 33913650
    [No Abstract]   [Full Text] [Related]  

  • 5. Polypill in Persons without Cardiovascular Disease.
    Alam A; Carey SA; Hall SA
    N Engl J Med; 2021 Apr; 384(17):1674. PubMed ID: 33913649
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypill in Persons without Cardiovascular Disease. Reply.
    Yusuf S; Joseph P; Pais P
    N Engl J Med; 2021 Apr; 384(17):1676-1677. PubMed ID: 33913653
    [No Abstract]   [Full Text] [Related]  

  • 9. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polypill for cardiovascular disease prevention.
    Dalton AR
    JAMA; 2013 Aug; 310(7):749. PubMed ID: 23989135
    [No Abstract]   [Full Text] [Related]  

  • 18. Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill.
    Doadrio AL; Sánchez-Montero JM; Doadrio JC; Salinas AJ; Vallet-Regí M
    Eur J Pharm Sci; 2017 Jan; 97():1-8. PubMed ID: 27818251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polypill for cardiovascular disease prevention--reply.
    Smith R; McCready T; Yusuf S
    JAMA; 2013 Aug; 310(7):749-50. PubMed ID: 23989317
    [No Abstract]   [Full Text] [Related]  

  • 20. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
    Ruiz J; Egli M
    Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.